Saeedi Fajr A, Hegazi Moustafa A, Alsaedi Hani, Alganmi Ahmed Hussain, Mokhtar Jawahir A, Metwalli Eilaf Majdi, Hamadallah Hanaa, Siam Ghassan S, Alaqla Abdullah, Alsharabi Abdullah, Alotaibi Sultan Ahmed
Department of Pediatrics, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah 80205, Saudi Arabia.
Department of Pediatrics, Faculty of Medicine in Mansoura, Mansoura University Children's Hospital, Mansoura 35516, Egypt.
Children (Basel). 2024 Apr 7;11(4):444. doi: 10.3390/children11040444.
Multidrug-resistant bacterial infections (MDRIs) constitute a major global threat due to increased patient morbidity/mortality and hospital stay/healthcare costs. A few studies from KSA, including our locality, addressed antimicrobial resistance in pediatric patients. This study was performed to recognize the incidence and clinical/microbiologic features of MDRIs in hospitalized pediatric patients. A retrospective cross-sectional study included pediatric patients < 18 years, admitted to King Abdulaziz University Hospital, between October 2021 and November 2022, with confirmed positive cultures of bacteria isolated from blood/body fluids. Patients' medical files provided the required data. MDR organisms (MDROs) were identified in 12.8% of the total cultures. The incidence of MDRIs was relatively high, as it was detected in 42% of patients and in 54.3% of positive bacterial cultures especially among critically ill patients admitted to the NICU and PICU. Pneumonia/ventilator-associated pneumonia was the main type of infection in 37.8% of patients with MDROs. was the most common significantly isolated MDRO in 39.5% of MDR cultures. Interestingly, a low weight for (no need for their as terminology weight for age is standard and well-known) was the only significant risk factor associated with MDROs ( = 0.02). Mortality was significantly higher ( = 0.001) in patients with MDROs (32.4%) than in patients without MDROs (3.9%). Patients who died including 85.7% of patients with MDROs had significantly longer durations of admission, more cultures, and utilized a larger number of antibiotics than the surviving patients ( = 0.02, = 0.01, = 0.04, respectively). This study provided a comprehensive update on the seriously alarming problem of MDROs, and its impacts on pediatric patients. The detected findings are crucial and are a helpful guide to decid for implementing effective strategies to mitigate MDROs.
多重耐药菌感染(MDRIs)由于患者发病率/死亡率增加以及住院时间/医疗成本上升,构成了重大的全球威胁。沙特阿拉伯王国(KSA)包括我们所在地区在内的一些研究探讨了儿科患者的抗菌药物耐药性。本研究旨在确定住院儿科患者中多重耐药菌感染的发生率以及临床/微生物学特征。一项回顾性横断面研究纳入了2021年10月至2022年11月期间入住阿卜杜勒阿齐兹国王大学医院、年龄小于18岁且血液/体液细菌培养确诊阳性的儿科患者。患者的病历提供了所需数据。在所有培养物中,12.8%鉴定出多重耐药菌(MDROs)。多重耐药菌感染的发生率相对较高,在42%的患者以及54.3%的阳性细菌培养物中检测到,尤其是在入住新生儿重症监护病房(NICU)和儿科重症监护病房(PICU)的重症患者中。肺炎/呼吸机相关性肺炎是37.8%的多重耐药菌患者的主要感染类型。在39.5%的多重耐药菌培养物中,[此处原文缺失具体细菌名称]是最常见的显著分离出的多重耐药菌。有趣的是,[此处原文表述混乱,疑似有误]低体重(由于年龄别体重术语标准且广为人知,无需使用“他们的体重”)是与多重耐药菌相关的唯一显著风险因素(P = 0.02)。多重耐药菌患者的死亡率(32.4%)显著高于无多重耐药菌患者(3.9%)(P = 0.001)。死亡患者,包括85.7%的多重耐药菌患者,其住院时间显著更长,培养次数更多,使用的抗生素数量也比存活患者更多(分别为P = 0.02、P = 0.01、P = 0.04)。本研究全面更新了多重耐药菌这一严重令人担忧的问题及其对儿科患者的影响。检测到的结果至关重要,有助于指导制定减轻多重耐药菌影响的有效策略。